FRANKFURT, July 29 German drugmaker Bayer saw underlying core earnings increase by one third in the second quarter, helped by strong overseas currencies and a gain in prescriptions of new drugs such a stroke prevention pill Xarelto.
Second-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose to 2.90 billion euros ($3.21 billion), compared with market expectations of 2.68 billion euros, while quarterly revenue gained 18 percent to 12.09 billion, also beating the analyst consensus.
Also read: Factors to watch on Jan 17
12:23 Morgan Stanley beats, has a record-breaking quarter for wealth management17
12:23 Sterling volatile as market speculates on ‘hard Brexit’; investors await May's speech15
13:48 Wells Fargo Profit Falls 5.4% as Mortgage Revenue Declines24
13:21 Bank of America profits surge on cost cuts, trading gains25